Vector Labs Ab04611-34.11 Anti-Alpha-synuclein [VH14 (NAC14)], Camelid VHH, His-tagged, (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: VH14 (NAC14)
Heavy Chain Modification: His-tagged
Synonyms: SNCA; NACP; PARK1; alpha-syn; α-Synuclein; α-syn; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor
Amount: 100 μg
Application Codes Clone: functional assay; therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: VHH
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody binds the hydrophobic non-amyloid component (NAC) of α-synuclein between amino acids 53-87. More specifically, this antibody showed high binding to linear epitope comprising aa 61-78 of alpha-syn. Alpha-synuclein is a small 140 amino acid presynaptic neuronal protein, a major component of Lewy bodies and a member of the synuclein family. Misfolding, abnormal accumulation, and secretion of α-Synuclein (α-Syn) are closely associated with synucleinopathies, including Parkinson’s disease (PD). α-syn is abundant in the brain, and smaller amounts are found in the heart, muscles, and other tissues. In the brain, α-syn is found mainly at the tips of neurons in the specialized structures known as presynaptic terminals and has been shown to comprise up to ∼1% of total proteins in the neuronal cytosol. Recent evidence suggests that α-synuclein (α-syn) can contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS).
Application Notes: The fusion of a proteasome-targeting PEST motif to this intrabody enhanced the solubility of the nanobody in cytoplasm and significantly enhanced degradation of the target protein, α-syn-GFP (PMID: 22929188). The in vivo therapeutic potential of gene therapy for delivery of proteasome-directed nanobodies selectively targeting α-syn was evaluated in a synuclein overexpression-based PD model. Post-mortem assessments of the substantia nigra (SN) of Sprague–Dawley rats after intracellular delivery of VH14-PEST showed that it markedly reduced the level of phosphorylated Serine-129 α-syn labeling relative to saline-treated animals (PMID: 30155513). A bifunctional antibody generated by fusing VH14 to a proteosome-targeting signal was able to counteract heterologous proteostatic effects of mutant α-Syn on mutant huntingtin Exon1 and protect against α-Syn toxicity using propidium iodide or Annexin V readouts (PMID: 27824888).

Product Class:	Purified
Clone ID:	VH14 (NAC14)
Heavy Chain Modification:	His-tagged
Synonyms:	SNCA; NACP; PARK1; alpha-syn; α-Synuclein; α-syn; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor
Amount:	100 μg
Application Codes Clone:	functional assay; therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	VHH
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody binds the hydrophobic non-amyloid component (NAC) of α-synuclein between amino acids 53-87. More specifically, this antibody showed high binding to linear epitope comprising aa 61-78 of alpha-syn. Alpha-synuclein is a small 140 amino acid presynaptic neuronal protein, a major component of Lewy bodies and a member of the synuclein family. Misfolding, abnormal accumulation, and secretion of α-Synuclein (α-Syn) are closely associated with synucleinopathies, including Parkinson’s disease (PD). α-syn is abundant in the brain, and smaller amounts are found in the heart, muscles, and other tissues. In the brain, α-syn is found mainly at the tips of neurons in the specialized structures known as presynaptic terminals and has been shown to comprise up to ∼1% of total proteins in the neuronal cytosol. Recent evidence suggests that α-synuclein (α-syn) can contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS).
Application Notes:	The fusion of a proteasome-targeting PEST motif to this intrabody enhanced the solubility of the nanobody in cytoplasm and significantly enhanced degradation of the target protein, α-syn-GFP (PMID: 22929188). The in vivo therapeutic potential of gene therapy for delivery of proteasome-directed nanobodies selectively targeting α-syn was evaluated in a synuclein overexpression-based PD model. Post-mortem assessments of the substantia nigra (SN) of Sprague–Dawley rats after intracellular delivery of VH14-PEST showed that it markedly reduced the level of phosphorylated Serine-129 α-syn labeling relative to saline-treated animals (PMID: 30155513). A bifunctional antibody generated by fusing VH14 to a proteosome-targeting signal was able to counteract heterologous proteostatic effects of mutant α-Syn on mutant huntingtin Exon1 and protect against α-Syn toxicity using propidium iodide or Annexin V readouts (PMID: 27824888).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews